Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136.

Slides:

Advertisements

Similar presentations

Summary Prepared by Melvyn Rubenfire, MD

Advertisements

NCEP ATP IV GuidelineS: 2013 Update

1 Prediabetes Screening and Monitoring. 2 Prediabetes Epidemiologic evidence suggests that the complications of T2DM begin early in the progression from.

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)

1 Prediabetes Comorbidities and Complications. 2 Common Comorbidities of Prediabetes Obesity CVD Dyslipidemia Hypertension Renal failure Cancer Sleep.

Epidemiology of Peripheral Vascular Disease Sohail Ahmed School of Population and Health Sciences.

CVD risk estimation and prevention: An overview of SIGN 97.

Lipid Disorders and Management in Diabetes

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Benefits of intensive multiple risk factor intervention.

Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care

Cholesterol quintile (mg/dL)

Diabetes Mellitus Type 2

Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.

The concept of Diabetes & CV risk: A lifetime risk challenge Diabetes & CV Risk: Routine practice versus guidelines Eberhard Standl, MD Professor of Medicine.

Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?

Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Epidemiology of Diabetes Mellitus by Santi Martini Departemen of Epidemiology Faculty of Public Health University of Airlangga.

AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.

European Society of Cardiology Cardiovascular diseases in women.

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College.

10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.

Blood pressure control in primary health care WORKSHOP

ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.

10 Points to Remember on An Effective Approach to High Blood Pressure ControlAn Effective Approach to High Blood Pressure Control Summary Prepared by Debabrata.

William C. Cushman, MD, FACP, FAHA Veterans Affairs Medical Center, Memphis, TN For The ACCORD Study Group.

Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.

ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:

Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.

The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]

Polypill x Aspirin Project Groups 3 and 4

Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and.

DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:

The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.

PUTTING PREVENTION FIRST Vascular Checks/ NHS Health Checks.

The Use of Aspirin for Primary Prevention of Cardiovascular Diseases

1 Effect of Ramipril on the Incidence of Diabetes The DREAM Trial Investigators N Engl J Med 2006;355 FM R1 윤나리.

Circulation. 2014;129: Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy.

CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.

Angela Aziz Donnelly April 5, 2016

1 Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled.

Antonio Coca, MD, PhD, FRCP, FESC

Nephrology Journal Club The SPRINT Trial Parker Gregg

Alcohol, Other Drugs, and Health: Current Evidence July–August 2017

Redefining Quality Care in T2DM Patients with CV Disease

Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.

Hypertension in the Post SPRINT era

What’s New in the 2013 ESC/ESH Hypertension Guideline

REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.

The Anglo Scandinavian Cardiac Outcomes Trial

Prevalence and control of cardiovascular risk factors using a German sample – Findings from the STAAB Cohort Study Theresa Tiffe1,3, Götz Gelbrich1,2,

First time a CETP inhibitor shows reduction of serious CV events

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Systolic Blood Pressure Intervention Trial (SPRINT)

The following slides highlight a presentation at the Late-Breaking Clinical Trials session of the American Heart Association Scientific Sessions, November.

Baseline characteristics of HPS participants by prior diabetes

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

The Hypertension in the Very Elderly Trial (HYVET)

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Managing Age-Related Clinical Issues in Hemophilia

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Factor Xa Inhibitors in Coronary Artery Disease

Goals & Guidelines A summary of international guidelines for CHD

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm

Section 6: Update on lipid treatment guidelines

Presentation transcript:

Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Classes of recommendations Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Levels of evidence Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Investigational algorithm for patients with coronary artery disease and diabetes mellitus Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Definition, classification, and screening of diabetes and pre-diabetic glucose abnormalities Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Criteria used for glucometabolic classification according to the WHO (1999) and ADA (1997 and 2003) (values are expressed as venous plasma glucose) Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Aetiological classification of glycaemia disordersa a Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Conversion factors between plasma and other vehicles for glucose values Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Fasting and post-load glucose levels identify different individuals with asymptomatic diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

FINnish Diabetes Risk SCore (FINDRISC) to assess the 10 year risk of type 2 diabetes in adults Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Epidemiology of diabetes, IGH, and cardiovascular risk Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Age- and gender-specific prevalence of diabetes in 13 European population-based cohorts included in the DECODE study Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Identification of subjects at high risk for CVD or diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Summary of the findings of four lifestyle intervention studies that aimed at preventing type 2 diabetes in subjects with IGT Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Treatment to reduce cardiovascular risk Lifestyle and comprehensive management Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Mean efficacy of pharmacological treatment options in patients with type 2 diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Percentage of patients achieving pre-defined intensive treatment targets in the Steno 2 study Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Glycaemic targets for the care of patients with diabetes as recommended by various organizations Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Potential downsides of pharmacological treatment modalities in patients with type 2 diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Suggested policy for the selection of glucose- lowering therapy according to the glucometabolic situation Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Treatment to reduce cardiovascular risk - Dyslipidaemia Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Subgroups of patients with DM in the major secondary prevention trials with statins and the proportionate risk reduction in patients with and without diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Treatment to reduce cardiovascular risk - Blood pressure Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Treatment effects of antihypertensive drugs in comparison with placebo or less intensive treatment as reported in randomized clinical trials Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Treatment effects expressed in hazard ratios (95% CI) in randomized clinical trials comparing different antihypertensive treatments in hypertensive patients with type 2 diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Management of CVD - Coronary artery disease Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Treatment options based on accumulated evidence Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Recommended treatment targets for patients with diabetes and CAD Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Diabetes and coronary revascularization Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Trials addressing diabetes and revascularization for multivessel disease Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Revascularization in diabetes patients with multivessel disease in the stent-era Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Heart failure and diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Arrhythmias: atrial fibrillation and sudden cardiac death Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Peripheral vascular disease Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Investigations of the peripheral circulation in diabetic patients Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Stroke Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Intensive care Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Published trials on intensive insulin therapy in critical illness Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Health economics and diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Direct medical costs for patients with type 2 diabetes in eight European countries and percentage of healthcare expenditure in the respective countries (1998) Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136